Specifically, the role of ROS regulatory components, such as NADPH oxidases (e.g., NOX2 and NOX4) and their downstream pathways (NRF2/AKT axis) in the progression of cardiac hypertrophy is well documented (22). The gene discussed is FMO5; the disease is cardiac hypertrophy.